Fennec Pharmaceuticals Reports 78% Revenue Jump as Pedmark Demand Reaches Record High
Fennec’s Pedmark is reportedly in demand as the only FDA-approved therapy to reduce cisplatin-induced hearing loss in pediatric patients.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
